Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

“Personalizing treatment in this way may lessen harmful side effects, reduce damage to healthy cells and make it more likely ...

Actithera’s radiopharma assets irreversibly bind to their targets, allowing for longer retention of the drug inside tumors.

The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.